

**The Issue:** All **UNEXPECTED** and **SERIOUS** Adverse Events must be reported to CERU with 48 hours of becoming aware of the event, regardless of the relationship of the study supplements to the event.

<b>UNEXPECTED</b>	<b>SERIOUS</b>
An Unexpected adverse event is any medical occurrence that is <b>NOT</b> expected due to the progression of the underlying disease or co-morbid illnesses	A Serious Adverse Event (experience) or reaction is any untoward medical occurrence that at any dose <sup>(1)</sup> : <ul style="list-style-type: none"> <li>• Results in death</li> <li>• Is life threatening</li> <li>• Requires or prolongs in-patient hospitalization</li> <li>• Results in persistent or significant disability/incapacity</li> <li>• May require medical or surgical intervention to prevent one of the other outcomes to defining serious.</li> </ul>

(1) Guidance for Industry, Clinical Safety Data Management Definitions and Standards for Expedited Reporting ICH Topic E2A Health Canada 1995.

**Solution** To be sure that we are compliant with these guidelines, two reports must be completed:

<b>SAE INITIAL REPORT</b>	<b>SAE FINAL REPORT</b>
<ul style="list-style-type: none"> <li>✓ Must be faxed to CERU <b>within 48 hrs</b> of becoming aware of the event.</li> <li>✓ Must be completed by the Site Investigator or the Study Coordinator in consultation with the Site Investigator; requires the signature of the Site Investigator.</li> <li>✓ Must include SAEs that occur during the study period, i.e. from the time of randomization to the end of the study period (actual ICU discharge, death or Study Day 30).</li> <li>✓ Certain aspects of the form may change (for example, the resolution date may not be known at the time of reporting) and this should be made clear in Final report.</li> </ul>	<ul style="list-style-type: none"> <li>✓ Must be faxed to CERU whichever comes first:                             <ul style="list-style-type: none"> <li>• end of study period =day 30 (from admission to ICU)</li> <li>• time of ICU d/c</li> <li>• time of ICU death</li> <li>• <b>within 15 days from becoming aware of the event if the event is fatal or life-threatening</b></li> </ul> </li> <li>✓ Must be completed by the Site Investigator by reviewing the Initial Report and the medical chart.</li> <li>✓ Must include patients admitting diagnosis, co-morbidities, a chronological complete narration of the events leading to the SAE, the nature of the SAE, action taken with the study supplements, the outcome and the relationship to the study supplements.</li> </ul>

**Concerns:** All SAEs must have an assessment concerning the relationship to investigational product. The relationship of the events to the products is based on the judgment of the Site Investigator.

**What to do:** The relationship to study supplements must be categorized as either *not related*, *unlikely related*, *possibly related* or *probably related*. **In the absence of a relationship to investigational product determination, or if there is any doubt concerning the relationship assessment, the relationship should be considered “possibly related” to the investigational product.** Please provide adequate description of the issues or the site investigator’s rationale for the determination.